Floatz logo

LEUPROLIDE

Breast Diseases

Fondazione IRCCS Istituto Nazionale dei Tumori, Milanoprotein_peptideActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Breast Diseases cohort.

Asset / SponsorPhaseRating
TRASTUZUMAB
Incepta Pharmaceuticals Ltd
Phase 3BB
SACUBITRIL VALSARTAN
Silesian Centre for Heart Diseases
Phase 4BB
Capecitabine
University of Southern California
Phase 3B
TAMOXIFEN
Fujian Cancer Hospital
Phase 2/3B
Letrozole
Fujian Cancer Hospital
Phase 2/3B

View all 39 →

Same molecule, other indications

LEUPROLIDE is also rated in:

prostate carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
metastatic prostate carcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
prostate neoplasmDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →